Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales
Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.
World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”
“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”
“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.
About World Cancer Day
World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.
Holland Venture investeert in WSO2 integrator Yenlo
Amsterdam, 19 november 2018 – Participatiemaatschappij Holland Venture investeert in Yenlo, dé integratiespecialist op het gebied van WSO2 open source middleware technologie. Het management en aandeelhouders hebben zich ten doel gesteld de komende jaren de groei van...
Holland Venture sells its shares in QSight IT to KPN
Amsterdam, October 3, 2017 - On the 2nd of October, Holland Venture and the other (management) the signed the acquisition contracts to sell their shares in QSight IT to Dutch telecom and ICT provider KPN. QSight IT is a leading Dutch player in the field of...
Holland Venture invests in LivAssured to support further development of the NightWatch
A groundbreaking detection system for nocturnal epileptic attacks Amsterdam, 20 September 2018 - Investment company Holland Venture invests with Oost NL and Health Innovations Fund in LivAssured, which developed the revolutionary NightWatch in collaboration...
Holland Venture closed a new fund to support innovation in healthcare
Amsterdam, 20 September 2018 – Holland Venture closed a new healthcare innovation fund which will invest in approx. 10 Dutch healthcare start-ups, active in the field of medical devices, diagnostics and digital health. The aim of the fund is to support entrepreneurs...
Investeerder Holland Venture start nieuw fonds voor innovaties in de zorg
Amsterdam, 20 september 2018 – Holland Venture is een nieuw zorginnovatie fonds gestart dat de komende jaren gaat investeren in circa 10 innovatieve ondernemers in de zorg. Het doel van het fonds is om ondernemers die actief zijn op het gebied van medical devices,...
Holland Venture investeert in LivAssured voor ontwikkeling NightWatch
Amsterdam, 20 september 2018 – Investeringsmaatschappij Holland Venture investeert met Oost NL en Health Innovations Fund in het bedrijf LivAssured, dat de revolutionaire NightWatch heeft ontwikkeld in samenwerking met neurologen en patiëntenverenigingen. De...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl